ARTICLE | Company News
Valentis, Schering deal
September 13, 2004 7:00 AM UTC
VLTS received $1 million from SCH after SCH decided to use VLTS' PINC polymer-based synthetic gene delivery and GeneSwitch gene regulation technologies for an additional undisclosed product developmen...